To evaluate the effects of PCDNA3.1-ERβ plasmid on the growth of prostate cancer in vivo, the orthotopic prostatic cancer models of the mice were developed to determine the antitumor efficacy. This evidence concerns the gene ESR2 and prostate carcinoma.